CAM
AIDX

Cresset Asset Management’s 20/20 Biolabs Inc AIDX Stock Holding History

Cresset Asset Management’s Portfolio AIDX Stock Details AIDX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$132K Sell
240,122
-24,246
-9% -$30.4K ﹤0.01% 1644
2026
Q1 		$497K Buy
+264,368
New +$1.12M ﹤0.01% 1071

Other funds holding AIDX

HF
HRT Financial New York $54.8B AUM 81.03% 1-Year Est. Return
Vanguard Fiduciary Trust
Vanguard Fiduciary Trust Malvern, Pennsylvania $454B AUM
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
AUB
Atlantic Union Bankshares Glen Allen, Virginia $5.99B AUM 23.66% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Citadel Advisors
Citadel Advisors Miami, Florida $875B AUM 40.89% 1-Year Est. Return
Bank of America
Bank of America Charlotte, North Carolina $1.55T AUM 33.47% 1-Year Est. Return
Susquehanna International Group
Susquehanna International Group Bala Cynwyd, Pennsylvania $1.28T AUM 58.89% 1-Year Est. Return
MP
McDonald Partners Cleveland, Ohio $412M AUM 34.27% 1-Year Est. Return
S
SignatureFD Atlanta, Georgia $7.49B AUM 24.82% 1-Year Est. Return

Cresset Asset Management's AIDX Position: Q2 2026 in Review

Cresset Asset Management reduced its 20/20 Biolabs Inc (AIDX) stake by 9.2% in Q2 2026, selling an estimated $30.4K and leaving 240,122 shares worth $132K. The position accounts for ﹤0.01% of the portfolio, ranked #1644.

Cresset Asset Management first reported a position in AIDX in Q1 2026 and has held it in 2 quarters since. The position peaked at $497K in Q1 2026. 15 funds tracked by Wall St. Rank hold AIDX as of Q2 2026.

  • Cresset Asset Management held 240,122 shares of 20/20 Biolabs Inc worth $132K as of Q2 2026.
  • Cresset Asset Management sold 24,246 20/20 Biolabs Inc shares in Q2 2026, an estimated $30.4K.
  • 20/20 Biolabs Inc made up ﹤0.01% of Cresset Asset Management's portfolio in Q2 2026, its #1644 holding.
  • Cresset Asset Management first reported a position in 20/20 Biolabs Inc in Q1 2026 and has held it in 2 quarters since.
  • Cresset Asset Management's 20/20 Biolabs Inc position peaked at $497K in Q1 2026.
  • 15 funds tracked by Wall St. Rank held 20/20 Biolabs Inc as of Q2 2026.

Based on Cresset Asset Management's 13F filing for Q2 2026, filed 14 Aug 2026.